14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.48 $4.41 Friday, 3rd May 2024 EVAX stock ended at $3.95. This is 1.54% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 3.64% from a day low at $3.85 to a day high of $3.99.
90 days $2.82 $4.74
52 weeks $0.470 $13.55

Historical Evaxion Biotech A/S prices

Date Open High Low Close Volume
Mar 01, 2021 $6.96 $7.34 $6.96 $7.08 19 408
Feb 26, 2021 $7.42 $7.42 $6.95 $6.98 31 554
Feb 25, 2021 $7.60 $7.85 $7.01 $7.41 90 835
Feb 24, 2021 $7.61 $7.88 $7.12 $7.50 16 698
Feb 23, 2021 $8.01 $8.01 $6.77 $7.28 182 040
Feb 22, 2021 $8.40 $8.61 $8.17 $8.17 30 140
Feb 19, 2021 $8.88 $8.95 $8.40 $8.40 97 396
Feb 18, 2021 $8.16 $8.98 $8.13 $8.69 103 585
Feb 17, 2021 $8.70 $8.78 $8.10 $8.24 128 076
Feb 16, 2021 $9.09 $9.40 $8.63 $8.75 131 064
Feb 12, 2021 $9.06 $9.50 $9.01 $9.18 61 818
Feb 11, 2021 $9.48 $9.75 $9.10 $9.12 70 864
Feb 10, 2021 $9.99 $9.99 $9.20 $9.40 248 540
Feb 09, 2021 $10.05 $10.10 $9.20 $9.35 339 883
Feb 08, 2021 $10.34 $10.34 $9.70 $9.95 506 844
Feb 05, 2021 $10.00 $10.00 $8.78 $9.89 1 400 368
Click to get the best stock tips daily for free!

About Evaxion Biotech A/S

Evaxion Biotech A/S Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various... EVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT